ViaNautis Bio to present its targeted polyNaut® nanovesicles (tPNVs) for the generation of in vivo CAR-T therapies at ASGCT Annual Meeting
- Targeted polyNaut® nanovesicles (tPNVs) are ViaNautis’ proprietary, polymer-based delivery platform for oligonucleotides enabling cell‑specific targeting through nanobody conjugation
- CD8 nanobody conjugated tPNVs are simple to manufacture and display high stability at 4°C
- CD8-tPNVs precisely target CD8-expressing immune cells in vitro and in vivo after intravenous or subcutaneous administration
Cambridge, UK – 7 May, 2026 – ViaNautis Bio (“ViaNautis”) , the biotech revolutionising genetic medicine with targeted polyNaut® nanovesicles, its versatile, disease-agnostic cell and gene therapy delivery system, today announced that it has been selected to present a poster at the American Society of Gene + Cell Therapy (ASGCT) 2026 Annual Meeting, taking place May 11-15, 2026 in Boston, Massachusetts.
